seekingalpha.com · 30 jun

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment

Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing risk.

seekingalpha.com · 10 jun

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

globenewswire.com · 27 may

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:

globenewswire.com · 13 may

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.

globenewswire.com · 12 may

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

globenewswire.com · 27 abr

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026

defenseworld.net · 19 abr

Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 47,814 shares of the company's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the sale, the director directly owned 3,482,888 shares of

defenseworld.net · 19 abr

Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 47,814 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the transaction, the director owned 3,482,888 shares in